| Literature DB >> 23555090 |
Ji-Hye Nah1, Hye-Jin Kim, Han-Na Lee, Mi-Jin Lee, Si-Sun Choi, Eung-Soo Kim.
Abstract
Polyketide belongs to a family of abundant natural products typically produced by the filamentous soil bacteria Streptomyces. Similar to the biosynthesis of most secondary metabolites produced in the Streptomyces species, polyketide compounds are synthesized through tight regulatory networks in the cell, and thus extremely low levels of polyketides are typically observed in wild-type strains. Although many Streptomyces polyketides and their derivatives have potential to be used as clinically important pharmaceutical drugs, traditional strain improvement strategies such as random recursive mutagenesis have long been practiced with little understanding of the molecular basis underlying enhanced polyketide production. Recently, identifying, understanding, and applying a novel polyketide regulatory system identified from various Omics approaches, has become an important tool for rational Streptomyces strain improvement. In this paper, DNA microarray-driven reverse engineering efforts for improving titers of polyketides are briefly summarized, primarily focusing on our recent results of identification and application of novel global regulatory genes such as wblA, SCO1712, and SCO5426 in Streptomyces species. Sequential targeted gene manipulation involved in polyketide biosynthetic reguation synergistically provided an efficient and rational strategy for Streptomyces strain improvement. Moreover, the engineered regulation-optimized Streptomyces mutant strain was further used as a surrogate host for heterologous expression of polyketide pathway.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23555090 PMCID: PMC3603650 DOI: 10.1155/2013/549737
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
wblA orthologs identified from various Streptomyces species.
|
|
Figure 1Time-dependent ACT volumetric productivities of wild-type S. coelicolor M145 (♦), S. coelicolor ΔwblA (■), S. coelicolor ΔwblAΔSCO1712 (▲), and S. coelicolor ΔwblAΔSCO1712Δ5426 (●) cultured in modified R5 media during 9 days in a 2-liter bioreactor [16].
Figure 2Time-dependent DXR/DNR/aklavinone volumetric productivities of S. peucetius WT (★), S. peucetius OIM (■), S. peucetius OIMΔwblA (▲), and S. peucetius OIMΔwblA /SCO4967 (●) [32].
Figure 3(A) Authentic TMC standard. (B) TMC volumetric productivities measured by quantitative HPLC analyses of the ethyl acetate-extracted culture broths were 1.69 mg · L−1 for the wild-type strain CK4412 (a), 5.44 mg · L−1 for the wblA-tmc disruptant (b), 4.04 mg · L−1 for CK4412-001/wblA-tmc (c), and 1.41 mg · L−1 for CK4412/wblA-tmc (d). (C) Time-dependent tautomycetin volumetric productivities of Streptomyces. sp. CK4412WT (♦) S. sp. CK4412/ΔwblA (■) [36].
Figure 4(a) Plasmid map of the pMMBL004, pAloeII-1 (pMMBL004 containing PstI fragment), and pAloeII-2 (pAloeII-1 containing actII-orf4); rep: replicon; ori: origin of replication; bla: β-lactamaseR; tsr: apramycinR; apr: apramycinR; oriT: origin of transfer. (b) Schematic representation of the aloesaponarin II biosynthetic pathway. Solid and dotted arrows represent presumed enzymatic and spontaneous steps, respectively. 3,8-DMAC: 3,8-dihydroxy-1-methyl-anthraquinone-2-carboxylic acid. R1 groups of aloesaponarin II and 3,8-DMAC are hydrogen and carboxylic acid, respectively. (c) Productions of aloesaponarin II and 3,8-DMAC in recombinant S. coelicolor strains. 1, S. coelicolor ΔACT/pMMBL004; 2, S. coelicolor ΔACTΔwblAΔSCO1712ΔSCO5426/pMMBL004; 3, S. coelicolor ΔACT/pAloeII-1; 4, S. coelicolor ΔACTΔwblAΔSCO1712ΔSCO5426/pAloeII-1; 5, S. coelicolor ΔACT/pAloeII-2; 6, S. coelicolor ΔACTΔwblAΔSCO1712ΔSCO5426/pAloeII-2; 7, S. coelicolor ΔACT/pAloeII-2; 8, S. coelicolor ΔACTΔwblAΔSCO1712ΔSCO5426/pAloeII-2; 1~6, liquid culture; 7~8, solid culture; ND, not detected [29].